Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1865 • 2019 ACR/ARP Annual Meeting
Improving Lupus Care Index Documentation in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Fatima Barbar-Smiley¹, Stephanie Lemle ¹, Cagri Yildirim-Toruner ¹, Edward Oberle ¹, Darby McDonald ¹, Vidya Sivaraman ² and Stacy Ardoin ¹, ¹Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital and The Ohio State University, Columbus, OH
Background/Purpose: Systemic lupus erythematosus (SLE) affects both adults and children with an estimated prevalence in children of 8/100,000. More than 1000 deaths related to SLE…
Abstract Number: 2109 • 2019 ACR/ARP Annual Meeting
Are Immunosuppressants a Risk Factor Associated with Mycobacterium Tuberculosis Infection in Colombian Patients with Systemic Lupus Erythematosus? A Case-control Study
Jaime Coral-Enriquez ¹, Mauricio Restrepo ², Gloria Vasquez ³, Carlos H Muñoz-Vahos ⁴, Daniel Jaramillo ⁵, Adriana Vanegas-García ⁴, Ruth Eraso ⁶, Johanna Hernández ⁷, Fabian Jaimes ⁸ and Luis Gonzalez², ¹Grupo de Reumatología, Universidad de Antioquia, Medellin, Colombia, ²Grupo de Reumatología, Division of Rheumatology, Department of Internal Medicine, School of Medicine Universidad de Antioquia, Medellín, Colombia, ³University of Antioquia, Medellin, Antioquia, Colombia, ⁴Grupo de Reumatología, Universidad de Antioquia, Medellín, Antioquia, Colombia, ⁵Rheumatology unit, Hospital Universitario San Vicente Fundación, Medellin, Colombia, ⁶Grupo de Reumatología, Universidad de Antioquia; Pediatric rheumatology unit, Hospital Pablo Tobón Uribe, Medellin, Colombia, ⁷Division of Rheumatology, Pediatric Department, School of Medicine, Universidad de Antioquia, Medellín, Colombia, ⁸Department of Epidemiology, Hospital Universitario San Vicente Fundación, Universidad de Antioquia, Medellín, Colombia, Medellín, Colombia
Background/Purpose: Tuberculosis (TB) infection is an important cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients, especially in developing countries. Previous studies have…
Abstract Number: 2524 • 2019 ACR/ARP Annual Meeting
24-Month Outcomes Associated with Belimumab in Black/African-American Patients with Systemic Lupus Erythematosus in a Clinical Practice Setting in the United States
Christopher Collins ¹, Gail Kerr ², Joan Von Feldt ³, Bernie Rubin ⁴, Arie Katz ³, Vanessa Castellano ⁵, Jake Chung ⁴ and Christopher Bell⁵, ¹MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ²Washington DC VA Medical Center, Georgetown and Howard Universities, Washington DC, DC, ³GSK, Philadelphia, PA, ⁴GSK, Phildelphia, PA, ⁵GSK, Research Triangle Park, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by diverse clinical manifestations and organ damage accrual. Black/African-American (B/AA) race is associated with…
Abstract Number: 2561 • 2019 ACR/ARP Annual Meeting
Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells
Jun Kikuchi¹, Hironari Hanaoka ¹, Shuntaro Saito ¹, Tatsuhiro Oshige ¹, Kazuoto Hiramoto ¹, Yuko Kaneko ¹, Noriyasu Seki ², Hideto Tsujimoto ² and Tsutomu Takeuchi ¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Mitsubishi Tanabe Pharma Corporation Sohyaku. Innovative Research Division, Toda-shi, Saitama, Japan
Background/Purpose: chievement of renal remission has been the target of the induction therapy in patients with active lupus nephritis (LN). Deep remission (DR) defined as…
Abstract Number: 2795 • 2019 ACR/ARP Annual Meeting
Patterns of Ambulatory Health Care Utilization and Medication Adherence Among Transition-Age Youth with Systemic Lupus Erythematosus
Joyce Chang¹, Andrea Knight ² and Erica Lawson ³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³University of California San Francisco Benioff Children’s Hospital, San Francisco, CA
Background/Purpose: Youth with child-onset systemic lupus erythematosus (SLE) transitioning from pediatric to adult health care systems may be at higher risk for poor outcomes than…
Abstract Number: 76 • 2019 ACR/ARP Annual Meeting
Effect of Ifnα and Costimulatory Blockade on Brain Infiltration in a Model of ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’
Hadijat Makinde¹, Chirag Raparia ², Anne Davidson ² and Carla Cuda ³, ¹Northwestern University, Chicago, IL, ²Feinstein Institutes for Medical Research, Manhasset, ³Northwestern University Feinberg School of Medicine, Division of Rheumatology, Chicago, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects many end organs including the brain. Despite a prevalence of over 50% in…
Abstract Number: 646 • 2019 ACR/ARP Annual Meeting
A Meta-Analysis of Anti-Ribosomal P Autoantibodies in Systemic Lupus Erythematosus: A Misunderstood Autoantibody
May Choi¹, Rachael Brown ², Katherine Buhler ³, Michael Mahler ⁴ and Marvin Fritzler ¹, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²University of Victoria, Victoria, Canada, ³University of Calgary, Calgary, Canada, ⁴Inova Diagnostics, San Diego, CA
Background/Purpose: Anti-ribosomal P (Rib-P) antibodies have become known as a highly specific biomarker for the diagnosis of SLE and potentially a biomarker for neuropsychiatric SLE…
Abstract Number: 812 • 2019 ACR/ARP Annual Meeting
Sex Differences in Autoimmunity and Cardiovascular Risk Could Be Associated with Altered Treg Phenotype and Lipoprotein Metabolism
George Robinson¹, Kirsty Waddington ¹, Anna Radziszewska ¹, Hannah Peckham ¹, David A Isenberg ², Yiannis Ioannou ¹, Coziana Ciurtin ³, Ines Pineda-Torra ¹ and Elizabeth Jury ¹, ¹University College London, London, United Kingdom, ²Centre for Rheumatology, London, United Kingdom, ³Centre for Adolescent Rheumatology, University College London London, UK, Londond, United Kingdom
Background/Purpose: Males and females have altered immune responses resulting in variation in autoimmune risk. Sex differences exist in the frequency and activity of immune-cell subsets…
Abstract Number: 1023 • 2019 ACR/ARP Annual Meeting
Neutrophils Are an Important Source of Microparticles in Lupus and Asymptomatic ANA+ Individuals
Carolina Muñoz-Grajales¹, Dennisse Bonilla ², Earl D. Silverman ³, Sindhu Johnson ⁴, Arthur Bookman ⁵, Zahi Touma ², Zareen Ahmad ⁶, Linda Hiraki ⁷ and Joan Wither ⁸, ¹University of Toronto, Toronto, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Canada, ⁴Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada, Toronto, Canada, ⁵University Health Network - Toronto Western Hospital, Toronto, Canada, ⁶Mount Sinai Hospital, Toronto, Canada, ⁷The Hospital for Sick Children, Toronto, Canada, ⁸University Health Network, Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Apoptotic microparticles (MPs) in the circulation of systemic lupus erythematosus (SLE) patients are enriched for nucleic acids and complexed with IgG (MP-IC), as compared…
Abstract Number: 1158 • 2019 ACR/ARP Annual Meeting
Investigating Health Literacy and Numeracy in an Academic Center Lupus Cohort
Mithu Maheswaranathan¹, Raeann Whitney ², Megan Clowse ², Amanda Eudy ² and Jennifer Rogers ², ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham
Background/Purpose: Up to 50% of American adults have basic or below basic health literacy and numeracy. Low health literacy is associated with increased health care…
Abstract Number: 1585 • 2019 ACR/ARP Annual Meeting
Endothelial Dysfunction and Arterial Stiffness in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis
Claudia Mendoza-Pinto¹, Adriana Rojas-Villarraga ², Nicolás Molano-González ³, Pamela Munguía-Realpozo ⁴, Socorro Méndez-Martínez ⁴, Aurelio López-Colombo ⁴ and Mario García-Carrasco ¹, ¹Systemic Autoimmune Diseases Research Unit, Hospital de Especialidades, UMAE CMNMAC - CIBIOR, Instituto Mexicano del Seguro Social. Department of Rheumatology and Immunology, Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Puebla, Mexico, ²FUCS -Fundación Universitaria de Ciencias de la Salud, Bogotá, Distrito Capital de Bogota, Colombia, ³Universidad del Rosario, Bogotá, Distrito Capital de Bogota, Colombia, ⁴Instituto Mexicano del Seguro Social, Puebla, Puebla, Mexico
Background/Purpose: Studies have reported increased cardiovascular (CV) morbidity and mortality in patients with SLE. In recent years, several non-invasive surrogates of CV disease risk have…
Abstract Number: 1623 • 2019 ACR/ARP Annual Meeting
Mortality in a SLE Inception Cohort of Hispanic Patients
Maria del Carmen Zamora Medina¹, Jessica Roldan Ortega ², Mario Cesar Ocampo Torres ³, Pilar Lara Reyes ¹, Ivon Bautista Mejia ¹, Alba Cicero Casarrubias ¹ and Juanita Romero-Diaz ⁴, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, MEXICO CITY, Mexico, ²Monterrey Institute of Technology and Higher Education, MEXICO CITY, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, MEXICO CITY, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico
Background/Purpose: To determine mortality and identify risk factors for mortality at 10 years in a mexican-mestizo SLE inception cohort at a tertiary care center in…
Abstract Number: 1897 • 2019 ACR/ARP Annual Meeting
Sexual Function and Health-related Quality of Life in Male Patients with Systemic Lupus Erythematosus, the Untold Story
Martín Valdez-López¹, Jonathan Campos-Guzmán ¹, Ana Barrera-Vargas ², Samuel Govea-Peláez ¹, Diana Gómez-Martín ¹, Jorge Alcocer-Varela ¹, Eduardo Aguirre-Aguilar ¹, Diana Padilla-Ortíz ³ and Javier Merayo-Chalico ¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico, ³Universidad De La Sabana, Bogotá, Cundinamarca, Colombia
Background/Purpose: Although SLE is uncommon in men, the disease is usually more severe and requires more aggressive immunosuppression in male patients. There are multiple studies…
Abstract Number: 2116 • 2019 ACR/ARP Annual Meeting
Serious Infection in Patients with Systemic Lupus Erythematosus, Lupus Nephritis and Rheumatoid Arthritis Compared to the General Population: Incidence Rates Using Real-World Claims Data
Lisa Lindsay¹, Ching-Yi Chuo ², Nicholas Jones ², Joshua Galanter ², Anna McGregor ² and Katie Tuckwell ², ¹Genentech Inc, SOUTH SAN FRANCISCO, CA, ²Genentech Inc, SOUTH SAN FRANCISCO
Background/Purpose: Patients with systemic lupus erythematosus (SLE), lupus nephritis (LN) and rheumatoid arthritis (RA) are at risk of serious infections (SIs) due to the impact…
Abstract Number: 2527 • 2019 ACR/ARP Annual Meeting
Cytokine and Autoantibody Profiles During Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
Ioannis Parodis¹, Emil Åkerström ¹, Christopher Sjöwall ², Azita Sohrabian ³, Andreas Jönsen ⁴, Alvaro Gomez ¹, Martina Frodlund ², Agneta Zickert ¹, Anders Bengtsson ⁴, Johan Rönnelid ³ and Iva Gunnarsson ¹, ¹Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Department of Clinical and Experimental Medicine, Rheumatology/Division of Neuro and Inflammation Sciences, Linköping University, Linköping, Sweden, ³Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁴Lund University, Lund, Sweden
Background/Purpose: The anti-BAFF monoclonal belimumab is approved for the treatment of systemic lupus erythematosus (SLE) since 2011. Effects of belimumab on anti-double stranded (ds)DNA levels,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].